These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

885 related articles for article (PubMed ID: 37481244)

  • 1. Impact of Antimicrobial Drug-Drug Interactions on Acute Kidney Injury after Allogeneic Hematopoietic Cell Transplantation.
    Wada F; Arai Y; Jo T; Mizumoto C; Kanda J; Kitawaki T; Nishikori M; Yamashita K; Takaori-Kondo A
    Transplant Cell Ther; 2023 Oct; 29(10):634.e1-634.e7. PubMed ID: 37481244
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Acute Kidney Injury in Hematopoietic Cell Transplantation Patients Receiving Vancomycin and Piperacillin/Tazobactam Versus Vancomycin and Cefepime.
    Clemmons AB; Bech CF; Pantin J; Ahmad I
    Biol Blood Marrow Transplant; 2018 Apr; 24(4):820-826. PubMed ID: 29292056
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Retrospective Cohort Study of the Incidence of Acute Kidney Injury with Vancomycin Area under the Curve-Based Dosing with Concomitant Piperacillin-Tazobactam Compared to Meropenem or Cefepime.
    Kiley PS; Pearston AP; Hodge LA; Kaplan MC; Baczek SM; Stanley JS; Wilson TJ; Soriano KM; Yao A; Shaeffer ZA; Talt IE; Cohen JA; Ingemi AI
    Antimicrob Agents Chemother; 2022 Aug; 66(8):e0004022. PubMed ID: 35867523
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Vancomycin with concomitant piperacillin/tazobactam vs. cefepime or meropenem associated acute kidney injury in the critically ill: A multicenter propensity score-matched study.
    Buckley MS; Komerdelj IA; D'Alessio PA; Rangan P; Agarwal SK; Tinta NC; Martinez BK; Ziadat DS; Yerondopoulos MJ; Kobic E; Kane-Gill SL
    J Crit Care; 2022 Feb; 67():134-140. PubMed ID: 34768175
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impact of acute kidney injury on overall survival in children and young adults undergoing allogeneic hematopoietic stem cell transplantation.
    Matsuoka D; Hirabayashi K; Murase T; Saito S; Nakazawa Y
    Pediatr Blood Cancer; 2021 Sep; 68(9):e29167. PubMed ID: 34086391
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Risk of Acute Kidney Injury and Clostridioides difficile Infection With Piperacillin/Tazobactam, Cefepime, and Meropenem With or Without Vancomycin.
    Lee JD; Heintz BH; Mosher HJ; Livorsi DJ; Egge JA; Lund BC
    Clin Infect Dis; 2021 Oct; 73(7):e1579-e1586. PubMed ID: 33382398
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Incidence of Acute Kidney Injury in Critically Ill Patients Receiving Vancomycin with Concomitant Piperacillin-Tazobactam, Cefepime, or Meropenem.
    Blevins AM; Lashinsky JN; McCammon C; Kollef M; Micek S; Juang P
    Antimicrob Agents Chemother; 2019 May; 63(5):. PubMed ID: 30782987
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparative Incidence of Acute Kidney Injury in Critically Ill Patients Receiving Vancomycin with Concomitant Piperacillin-Tazobactam or Cefepime: A Retrospective Cohort Study.
    Hammond DA; Smith MN; Painter JT; Meena NK; Lusardi K
    Pharmacotherapy; 2016 May; 36(5):463-71. PubMed ID: 26952639
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Risk factors for acute kidney injury in patients undergoing allogeneic hematopoietic stem cell transplantation.
    Yu ZP; Ding JH; Chen BA; Liu BC; Liu H; Li YF; Ding BH; Qian J
    Chin J Cancer; 2010 Nov; 29(11):946-51. PubMed ID: 20979694
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Risk assessment for acute kidney injury after allogeneic hematopoietic stem cell transplantation based on Acute Kidney Injury Network criteria.
    Mori J; Ohashi K; Yamaguchi T; Ando M; Hirashima Y; Kobayashi T; Kakihana K; Sakamaki H
    Intern Med; 2012; 51(16):2105-10. PubMed ID: 22892486
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical Features of Acute Kidney Injury in the Early Post-Transplantation Period Following Reduced-Intensity Conditioning Allogeneic Hematopoietic Stem Cell Transplantation.
    Vergara-Cadavid J; Johnson PC; Kim HT; Yi A; Sise ME; Leaf DE; Hanna PE; Ho VT; Cutler CS; Antin JH; Gooptu M; Kelkar AH; Wells SL; Nikiforow S; Koreth J; Romee R; Soiffer RJ; Shapiro RM; Gupta S
    Transplant Cell Ther; 2023 Jul; 29(7):455.e1-455.e9. PubMed ID: 37015320
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Risk of Acute Kidney Injury in Patients on Concomitant Vancomycin and Piperacillin-Tazobactam Compared to Those on Vancomycin and Cefepime.
    Navalkele B; Pogue JM; Karino S; Nishan B; Salim M; Solanki S; Pervaiz A; Tashtoush N; Shaikh H; Koppula S; Koons J; Hussain T; Perry W; Evans R; Martin ET; Mynatt RP; Murray KP; Rybak MJ; Kaye KS
    Clin Infect Dis; 2017 Jan; 64(2):116-123. PubMed ID: 27986669
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparative incidence of acute kidney injury in patients on vancomycin therapy in combination with cefepime, piperacillin-tazobactam or meropenem.
    Rungkitwattanakul D; Ives AL; Harriott NG; Pan-Chen S; Duong L
    J Chemother; 2022 Apr; 34(2):103-109. PubMed ID: 34424136
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluating the Nephrotoxicity of Area-under-the-Curve-Based Dosing of Vancomycin with Concomitant Antipseudomonal Beta-Lactam Antibiotics: A Systematic Review and Meta-Analysis.
    Chiu CY; Sarwal A
    Medicina (Kaunas); 2023 Mar; 59(4):. PubMed ID: 37109649
    [No Abstract]   [Full Text] [Related]  

  • 15. Phenotypes and Baseline Risk Factors of Acute Kidney Injury in Children After Allogeneic Hematopoietic Stem Cell Transplantation.
    Daraskevicius J; Azukaitis K; Dziugeviciute-Tupko J; Peciulyte M; Planciunaite R; Vaitkeviciene G; Rascon J; Jankauskiene A
    Front Pediatr; 2020; 8():499. PubMed ID: 32984211
    [No Abstract]   [Full Text] [Related]  

  • 16. [Risk of Acute Kidney Injury in Patients Treated with Vancomycin and Piperacillin/Tazobactam Compared to Vancomycin and Meropenem or Doripenem: A Retrospective Cohort Study].
    Ide N; Sato S; Sawaguchi K
    Yakugaku Zasshi; 2019; 139(12):1609-1614. PubMed ID: 31787651
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Clinical study on acute kidney injury after myeloablative allogeneic hematopoietic cell transplantation].
    Bao YS; Jiang EL; Wang M; Huang Y; Wei JL; Yang DL; Feng SZ; Han MZ
    Zhonghua Xue Ye Xue Za Zhi; 2008 Jun; 29(6):401-4. PubMed ID: 19031744
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Incidence of Nephrotoxicity Among Pediatric Patients Receiving Vancomycin With Either Piperacillin-Tazobactam or Cefepime: A Cohort Study.
    Cook KM; Gillon J; Grisso AG; Banerjee R; Jimenez-Truque N; Phillips EJ; Van Driest SL
    J Pediatric Infect Dis Soc; 2019 Jul; 8(3):221-227. PubMed ID: 29590376
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A Time-to-Event Model for Acute Kidney Injury after Reduced-Intensity Conditioning Stem Cell Transplantation Using a Tacrolimus- and Sirolimus-based Graft-versus-Host Disease Prophylaxis.
    Piñana JL; Perez-Pitarch A; Garcia-Cadenas I; Barba P; Hernandez-Boluda JC; Esquirol A; Fox ML; Terol MJ; Queraltó JM; Vima J; Valcarcel D; Ferriols-Lisart R; Sierra J; Solano C; Martino R
    Biol Blood Marrow Transplant; 2017 Jul; 23(7):1177-1185. PubMed ID: 28396159
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Nephrotoxicity during Vancomycin Therapy in Combination with Piperacillin-Tazobactam or Cefepime.
    Rutter WC; Cox JN; Martin CA; Burgess DR; Burgess DS
    Antimicrob Agents Chemother; 2017 Feb; 61(2):. PubMed ID: 27895019
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 45.